This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): REN-1654
Description: REN-1654 reduces inflammation in the nervous system by decreasing the release of tumor necrosis factor a (TNFa), a signaling molecule used by the immune system and certain cells in the nervous system. During inflammation, TNFa is thought to play a key role both in directly causing an increase in pain signaling and in damaging nerves by increasing the inflammatory response.
Deal Structure: This compound was originally developed by Renovis. In September 2007, Evotec AG and Renovis announced that they have entered into a definitive agreement under which Evotec will acquire Renovis. This acquisition was closed in May 2008.
Pink Sheet Office for Human Research Trials
Additional information available to subscribers only: